Analysts name 3 ASX shares to buy now

These shares are rated very highly…

| More on:
A man holds up his hand with 3 fingers up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a good number of shares for investors to choose from on the Australian share market.

Three that could be top options right now are listed below. Here's why analysts think they are in the buy zone:

Elders Ltd (ASX: ELD)

Elders is one of Australia's largest agribusiness companies. After going through a very tough time during the 2010s, things are now looking increasingly positive for the company. This has been driven largely by the success of Elders' transformation plan and acquisitions. Pleasingly, Goldman Sachs is confident this positive form will continue. So much so, its analysts have a conviction buy rating and $15.65 price target on its shares. The broker likes Elders due to the rationalisation of the rural services industry, margin expansion through backward integration, its strong balance sheet and cash flow, and the benefits of its large scale systems modernisation project.

Healius Ltd (ASX: HLS)

Healius is one of Australia's leading pathology and diagnostic imaging providers. Its healthcare network has been performing particularly positively over the last 18 months thanks to a robust performance from its core business and elevated demand for COVID-19 testing. The good news is that this has continued in FY 2022. For example, during the first quarter, Healius reported a 43.7% increase in group quarterly revenue to $689.9 million. And while its growth rate will inevitably slow once testing demand eases, the team at Macquarie still see a lot of value in its shares at the current level. The broker currently has an outperform rating and $5.65 price target on its shares.

ResMed Inc. (ASX: RMD)

ResMed is a medical device company with a focus on the sleep treatment market. Its masks and software help sufferers of afflictions such as sleep apnoea and COPD. These are huge markets, which provide ResMed with a long runway for growth over the next decade. Particularly given its industry leadership position and high level of investment in research and development. The latter is keeping its portfolio filled with world class products. Morgans is a fan of ResMed and has an add rating and $40.80 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Elders Limited and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man in a blue collared shirt sits at his desk doing a single fist pump as he watches the Appen share price rise on his laptop
Broker Notes

These ASX 200 stocks could rise 30% to 40%

Analysts are tipping these shares to go to the moon. Let's find out why.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Man pointing at a blue rising share price graph.
Technology Shares

Up 30% in a month, this ASX 200 tech share is 'a compelling opportunity': expert

Analysts from listed investment company WAM Capital say this ASX 200 tech stock is worth watching.

Read more »

An executive in a suit smooths his hair and laughs as he looks at his laptop feeling surprised and delighted.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

View of a mine site.
Broker Notes

How much upside does Macquarie tip for Deterra Royalties shares?

Deterra Royalties offers ASX investors a different way to invest in global mining.

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.
Broker Notes

Broker reveals outlook for ASX dividend shares amid volatile market

Peter Gardner from Plato Investment Management tells ASX investors where to look for dividend income this year.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Leading broker puts buy rating on Zip shares

Big returns could be on offer for investors according to its analysts.

Read more »

gaming asx share price rise represented by slot machine paying jackpot
Broker Notes

What does Macquarie expect from Aristocrat Leisure shares when it reports on 14 May?

Here's what the broker is expecting from this gaming technology company next week.

Read more »